Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TumoCure · 1 trial · 1 indication
Cumulative rate of treatment - related serious adverse events (SAEs) throughout the follow up period (90 days)
| Arm | Type | Description |
|---|---|---|
| TumoCure Treatment | EXPERIMENTAL | Subjects will be treated with a single intra-tumor injection of TumoCure, containing the polymeric delivery system and the Cisplatin hemotherapy agent at a dose of 100mg. |
| Name | Type | Description |
|---|---|---|
| TumoCure | COMBINATION_PRODUCT | TumoCure is a polymer-based gel, loaded with Cisplatin in a dose of 100mg (10% w/w), injected to head and neck tumors locally in a single injection. |
Inclusion Criteria: 1. Male and female aged 18-80 years. 2. Subjects who are willing to comply with study procedures. 3. Subjects who are mentally and cognitively capable and who are capable of understanding and signing the informed consent. 4. Subjects with a known diagnosis of primary head and ne...
Top 20 of 58 competitors
TumoCure is an investigational small molecule being developed for head and neck cancer. It is currently in a Phase 1 clinical trial for patients with progressive or radio-resistant primary head and neck tumors. The drug is administered as a single intra-tumoral injection and is being studied for safety, tolerability, and initial efficacy.
TumoCure is a polymer-based cisplatin-loaded gel. It delivers cisplatin, a chemotherapy agent, directly into the tumor through an intra-tumoral injection. The gel formulation is designed to allow localized delivery of the drug to the tumor site.
TumoCure is being developed by cbdMD, Inc., a company traded under the ticker YCBD. The drug is currently in Phase 1 clinical development for head and neck cancer.
TumoCure is in Phase 1 clinical development. It is currently being evaluated in a Phase 1b study that is recruiting participants. The drug is investigational and has not been approved by regulatory authorities.
TumoCure is being studied in a single clinical trial with the identifier NCT05200650. This is a Phase 1b, single-arm, open-label, multi-center study in Israel. The trial is recruiting 20 participants with progressive or radio-resistant primary head and neck tumors.
Yes, TumoCure is the same as IntraGel's polymer-based cisplatin-loaded gel. The clinical trial NCT05200650 refers to the drug as TumoCure and describes it as IntraGel's polymer-based cisplatin-loaded gel.